Serum Institute resumes exports of Covishield vaccine
- The vaccine maker has cumulatively produced 1.25 billion dosages up until now.
- SII’s supply of doses through COVAX is expected to increase substantially into Quarter 1 2022: SII
- First batches of Covishield vaccines left the manufacturing facility in Pune, said the business.
Serum Institute of India on Friday stated it has resumed exports of its COVID-19 vaccine, Covishield to low- and middle-income nations with the very first batch of consignment leaving its Pune center.
The vaccine maker has cumulatively produced 1.25 billion doses up until now, a company statement said.
“The first batches of its COVISHIELD COVID-19 vaccine left the SII manufacturing center in Pune earlier today, for circulation to low- and middle-income countries through the COVAX mechanism,” it stated. “SII’s supply of doses by means of COVAX is anticipated to increase considerably into Quarter 1 2022,” it included.
ALSO READ: India on alert after brand-new Covid variation discovered in Africa, govt requires stringent screening of travellers
Latest India News
Published at Fri, 26 Nov 2021 06:50:38 -0600